Blockade of TRPV1 Inhibits Methamphetamine-induced Rewarding Effects

• Published in: Scientific reports Vol. 8; no. 1; pp. 882 - 12
• Main Authors: Tian, Yu-Hua, Ma, Shi-Xun, Lee, Kwang-Wook, Wee, Sunmee, Koob, George F., Lee, Seok-Yong, Jang, Choon-Gon
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.01.2018; Nature Publishing Group
• Subjects: 13/1; 631/378/1788; 631/378/2586; 64/110; 64/60; 82/29; Addictions; Capsaicin receptors; Capsazepine; Caudate-putamen; Dopamine; Dopamine transporter; Drug addiction; Gene expression; Humanities and Social Sciences; Methamphetamine; Microdialysis; mRNA; multidisciplinary; Neostriatum; Nucleus accumbens; Place preference conditioning; Polymerase chain reaction; Reinforcement; Rodents; Science; Science (multidisciplinary); Self-administration
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-19207-2

Methamphetamine (MAP) is the most widely used psychostimulant in the world, but the exact mechanisms underlying MAP addiction are not yet fully understood. Recent studies have identified the distribution of TRPV1 in several brain regions that are related to drug addiction, including nucleus accumbens (NAc) and dorsal striatum (DSt). In the present study, we performed conditioned place preference (CPP) and self-administration tests to examine the effects of capsazepine (CPZ) and SB366791 (SB) on MAP reward. We found that both CPZ and SB significantly inhibited MAP-induced CPP and self-administration; in contrast, TRPV1 knock-out (KO) mice did not develop MAP-induced CPP. Real-time RT-PCR, Western blot and quantitative autoradiographic tests showed up-regulation of TRPV1 mRNA and protein expression in the NAc and/or DSt regions of mice exhibiting MAP-induced CPP. In addition, an in vivo microdialysis experiment showed that CPZ dramatically reduced dopamine (DA) levels in the NAc region of MAP-treated mice. Furthermore, attenuated dopamine transporter (DAT) binding levels in the NAc and DSt regions of MAP-induced CPP mice were reversed by CPZ. Together, these data suggest that TRPV1 plays an important role in MAP reward via the modulation of DA release and DAT density, thereby providing a novel therapeutic target for MAP addiction.